GlassScriptPhysician profile
Amanda J Wickson
NPI 1710177464
$4,169.51
in general payments reported to CMS, 2019-2025
32 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,494 · 2022: $1,207 · 2023: $92.33 · 2024: $234 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,305.11 | 2021 | |
| Abbvie INC. | $356.49 | 2021-2025 | |
| Novo Nordisk INC | $303.70 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $276.65 | 2021-2023 | |
| Lilly USA, LLC | $224.68 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.55 | 2021-2022 | |
| Glaxosmithkline, LLC. | $135.29 | 2021-2022 | |
| Daiichi Sankyo INC. | $130.17 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $110.07 | 2024 | Voquezna |
| Amarin Pharma, INC. | $108.22 | 2021-2022 | |
| Althera Pharmaceuticals LLC | $101.98 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.73 | 2022 | |
| Esperion Therapeutics, INC. | $95.70 | 2021-2022 | |
| Kaleo, INC. | $87.60 | 2021-2022 | |
| Abbott Laboratories | $82.69 | 2021-2025 | Proclaim |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.83 | 2021-2024 | Airsupra |
| Paratek Pharmaceuticals, INC. | $50.58 | 2025 | Nuzyra, Xhance |
| Pfizer INC. | $45.20 | 2021-2022 | |
| Corcept Therapeutics | $40.73 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $38.63 | 2021 | |
| Genentech USA, INC. | $35.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.71 | 2021-2022 | |
| Medtronic, INC. | $31.00 | 2022-2023 | Intellis Adaptivestim |
| Amgen INC. | $25.33 | 2021 | |
| Currax Pharmaceuticals LLC | $25.00 | 2021-2024 | Onzetra Xsail, Contrave |
| Edwards Lifesciences Corporation | $23.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.93 | 2022 | |
| Horizon Therapeutics Plc | $16.63 | 2022 | |
| Sanofi Pasteur INC. | $16.12 | 2022 | |
| Merck Sharp & Dohme LLC | $15.49 | 2021 | |
| Bausch Health US, LLC | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.